Erfolgreiche Oralair-Registrierung in Kanada
Antony (France), 21 March 2012 - Stallergenes SA (Euronext Paris CAC small) announced today that Health Canada has approved Oralair™. Oralair™ is a sublingual grass pollen immunotherapy tablet for the treatment of moderate to severe seasonal grass pollen allergic rhinitis with or without conjunctivitis.
With this approval, Oralair™ becomes the first allergen immunotherapy tablet to be registered in North America.
<- Zurück zu: